Morning Tea

SEBI Certified – Research Analyst www.choiceindia.com
Global View
India Update
Today’s Event/ Stock in News
Dr. Reddy's Laboratories has launched ESOMEPRAZOLE Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg, a therapeutic equivalent
generic version of NEXIUM (Esomeprazole Magnesium) Delayed-Release Capsules in the US market on September 25, 2015, following the
approval by the United States Food & Drug Administration (USFDA).The NEXIUM (Esomeprazole Magnesium) Delayed-Release Capsules brand
and generic had US sales of approximately $5.2 billion MAT for the most recent twelve months ending in July 2015 according to IMS Health. The
company's ESOMEPRAZOLE Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg are available in bottle count size of 30.Dr.
Technical Outlook : On daily chart, the stock has been taking support of horizontal trend line at 3870 levels. Price has retraced from almost 50%
Fibonacci Retracement of its previous rally from 3266.50 to 4327.50 levels. Moreover, prices are trading above 60 DEMA, which suggest
medium term trend is up. Moreover, momentum indictor RSI have hovering around 60 levels on daily chart which gives positive confirmation to
the prices. So for trading perspective, one could Buy in the range of 4177-4191 for the Target of 4275 with the SL of 4135.
SPARC on Monday fell 2.62% to close at Rs.375.80, a piece on BSE after the US Food and Drugs Administration (US FDA) withdrew its approval
for anti-epileptic drug made by the firm. The US FDA has issued a Complete Response Letter (CRL) to SPARC on its New Drug Application for
Elepsia XR (Levetiracetam extended-release tablets 1,000mg and 1,500mg). In a note, the agency said it has revoked the approval issued to
SPARC in March 2015, citing compliance issues at Sun’s Halol plant in Gujarat. SPIL is working with US FDA in resolving the CGMP (current good
manufacturing practices) deviations at the facility and has taken several corrective measures. The withdrawal of US FDA approval comes at a
time when SPARC is evaluating marketing partners for commercialization of the drug.
Technical Outlook: On daily chart, prices have been facing resistance of falling trend line at 390 levels. Prices has given gap down opening with
above average volumes, which suggests more down side can be seen in few trading session. Moreover, prices are trading below 100 DEMA on
daily chart, which indicating that medium to long trend is down. Momentum indicator RSI has remained below 60 levels on daily chart which
gives negative confirmation to the prices. So for trading perspective, one could Sell in the range of 375-377 for the Target of 367 with the SL of
381
DRRDDY
SPARC
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Morning Tea
29th Sept 2015
Sell in the range of 375-377 for the Target of 367 with the SL of 381
Buy in the range of 4177-4191 for the Target of 4275 with the SL of 4135
US stocks finished sharply lower on Monday and were on track for their worst quarter in four years as investors worried about the health of
China's economy and its potential impact on the timing of a US interest rate increase. US consumer spending rose more than expected in
August, according to another report, appearing to add to the case for an interest rate increase this year. The Federal Reserve held off from
raising rates at its September meeting, citing concerns about the global economy, notably China, among other factors. New York Federal
Reserve President William Dudley on Monday suggested the central bank could pull the trigger as soon as October. The Dow Jones industrial
average fell 1.92 percent to end at 16,001.89 points. The S&P 500 lost 2.57 percent to 1,881.77 and the Nasdaq Composite dropped 3.04
percent to finish at 4,543.97.
Asian shares skidded to three-week lows and the dollar sagged on Tuesday, after weak Chinese data rekindled worries about its fragile economy
and led to sharp losses on Wall Street. Chinese industrial companies' profits fell at their fastest rate in four years, official data showed on
Monday, sparking fresh fears about the strength of that country's economy ahead the final reading of China's Caixin Purchasing Managers'
Index on Thursday. The Fed held off from raising interest rates at its meeting earlier this month, citing worries about the global economy,
particularly China. US non-farm payrolls on Friday could add more clarity to the timing of a US policy move, and prop up the sagging greenback.
The Shanghai Composite index traded at -1.63% to 33051.01, Hang Seng index traded at -3.71 % to 20429.02., Japan's benchmark Nikkei 225
index traded at -2.85% to 17155.85, South Korea's Kospi index down by –0.22 % to 1942.85 levels. The SGX Nifty suggests a negative opening for
our markets as it is trading at 7711, down by -121.50 points.

Bulk Deal
Corporate Action / Result Calendar
Morning Tea
29th Sept 2015
Security in Ban
Corporate Action:
Sr.No DealDate SecurityCode SecurityName ClientName DealType Quantity Price
1 28.09.15 GVKPIL GVKPower& Infrastructur GVSANJAY REDDY SELL 150,00,000 6.95
2 28.09.15 GVKPIL GVKPower& Infrastructur VERTEXPROJECTSLIMITED BUY 150,00,000 6.95
3 28.09.15 GOLDINFRA Goldstone InfratechLtd. SHAH JAYANT HIRALAL BUY 3,57,474 16.09
4 28.09.15 DEEPIND DeepIndustries Ltd BAKSHUPROPERTY PVT LTD BUY 2,03,500 172.48
5 28.09.15 DEEPIND DeepIndustries Ltd BAKSHUPROPERTY PVT LTD SELL 2,03,500 169.25
6 28.09.15 DEEPIND DeepIndustries Ltd GKNSECURITIES BUY 2,00,064 166.33
7 28.09.15 DEEPIND DeepIndustries Ltd GKNSECURITIES SELL 2,00,064 168.92
8 28.09.15 ASIANTILES AsianGranitoIndia Limit HARIDARSHANSALESPVT LTD SELL 1,62,181 122.00
9 28.09.15 ASIANTILES AsianGranitoIndia Limit CHERICERAMICSPRIVATE LIMITED BUY 1,50,000 122.00
10 28.09.15 ASIANTILES AsianGranitoIndia Limit IVORY CONSULTANTSPVT LTD. SELL 1,37,819 122.00

Contact Us
www.choiceindia.com
www.choiceindia.comcustomercare@choiceindia.com
Disclaimer
This is solely for information of clients of Choice Broking and does not construe to be an investment advice. It is also not intended as an offer or solicitation for the purchase and sale of any financial
instruments. Any action taken by you on the basis of the information contained herein is your responsibility alone and Choice Broking its subsidiaries or its employees or associates will not be liable in
any manner for the consequences of such action taken by you. We have exercised due diligence in checking the correctness and authenticity of the information contained in this recommendation, but
Choice Broking or any of its subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this recommendation or any action taken on basis of this information. Technical analysis studies market psychology, price patterns and volume levels. It is used to forecast
future price and market movements. Technical analysis is complementary to fundamental analysis and news sources. The recommendations issued herewith might be contrary to recommendations
issued by Choice Broking in the company research undertaken as the recommendations stated in this report is derived purely from technical analysis. Choice Broking has based this document on
information obtained from sources it believes to be reliable but which it has not independently verified; Choice Broking makes no guarantee, representation or warranty and accepts no responsibility
or liability as to its accuracy or completeness. The opinions contained within the report are based upon publicly available information at the time of publication and are subject to change without
notice. The information and any disclosures provided herein are in summary form and have been prepared for informational purposes. The recommendations and suggested price levels are intended
purely for trading purposes. The recommendations are valid for the day of the report however trading trends and volumes might vary substantially on an intraday basis and the recommendations may
be subject to change. The information and any disclosures provided herein may be considered confidential. Any use, distribution, modification, copying, forwarding or disclosure by any person is
strictly prohibited. The information and any disclosures provided herein do not constitute a solicitation or offer to purchase or sell any security or other financial product or instrument. The current
performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investments will achieve any targeted rates of return, and there is no guarantee
against the loss of your entire investment.
POTENTIAL CONFLICT OF INTEREST DISCLOSURE (as on date of report) Disclosure of interest statement – • Analyst interest of the stock /Instrument(s): - No. • Firm interest of the stock /
Instrument (s): - No.
Research Team
Mr. Sumeet Bagadia Associate Director
Kunal Parmar Research Associate
Ritesh Patel Research Associate
Amit Pathania Research Associate
Vikas Chaudhari Research Associate
Rajnath Yadav Research Associate
Satish Kumar Research Associate
Morning Tea
29th Sept 2015
Kunal Parmar
Digitally signed by Kunal Parmar
DN: cn=Kunal Parmar, o=Choice Equity Broking Pvt Ltd.,
ou=Research Dept., email=kunal.parmar@choiceindia.com,
c=IN
Date: 2015.09.29 08:52:04 +05'30'

Morning Tea

More Related Content

What's hot

Viewers also liked

Similar to Morning Tea

Recently uploaded

Morning Tea